GNSN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Revenue From PIC And ABSGenus earns recurring revenue via multi-year customer relationships in PIC and ABS where producers regularly repurchase genetics and replacement stock. This repeat demand from integrated supply chains creates predictable revenue streams and reduces dependence on one-off sales, supporting steadier long-term cash flows and planning.
Proprietary R&D And Differentiated GeneticsSustained R&D investment produces differentiated genetic lines and intellectual property that raise switching costs for customers. Over months to years, superior genetics can deliver measurable productivity gains to producers, supporting pricing power, customer stickiness, and a durable competitive moat versus commodity genetics suppliers.
Robust Operating Cash GenerationStrong operating cash flow gives Genus internal funding for R&D, selective M&A, and working capital without heavy reliance on external financing. Consistent cash generation enhances financial flexibility, allowing the company to sustain investments that underpin long-term growth and to manage cyclical pressures in livestock markets.
Bears Say
Relatively Low Net Profit MarginDespite healthy gross margins and operational efficiency, a low net margin signals limited retained earnings after operating costs and non-operating items. Over time this can constrain reinvestment, limit buffer for shocks, and reduce the ability to fund sustained R&D or return capital without improving cost structure or pricing.
Volatile Free Cash Flow ConversionVariability in free cash flow reduces the predictability of funds available for growth, debt reduction, or shareholder returns. Structural investments in breeding programs and capital-intensive operations require steady conversion; persistent volatility can force trade-offs between investment and balance sheet management, weakening long-term execution.
Exposure To Biosecurity And Livestock Health RisksGenus's earnings depend on herd health and livestock production volumes. Disease outbreaks or prolonged health issues can materially reduce demand for genetics, disrupt supply chains, and raise customer risk aversion. These structural industry risks can depress revenue and lengthen recovery timeframes for genetic program adoption.
GNSN FAQ
What was Genus plc’s price range in the past 12 months?
Currently, no data Available
What is Genus plc’s market cap?
Genus plc’s market cap is $33.04B.
When is Genus plc’s upcoming earnings report date?
Genus plc’s upcoming earnings report date is Sep 10, 2026 which is in 47 days.
How were Genus plc’s earnings last quarter?
Genus plc released its earnings results on Feb 26, 2026. The company reported $13.995 earnings per share for the quarter, beating the consensus estimate of $10.645 by $3.35.
Is Genus plc overvalued?
According to Wall Street analysts Genus plc’s price is currently Undervalued.
Does Genus plc pay dividends?
Genus plc does not currently pay dividends.
What is Genus plc’s EPS estimate?
Genus plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genus plc have?
Genus plc has 66,539,440 shares outstanding.
What happened to Genus plc’s price movement after its last earnings report?
Genus plc reported an EPS of $13.995 in its last earnings report, beating expectations of $10.645. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Genus plc?
Currently, no hedge funds are holding shares in MX:GNSN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genus plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$685.00 (― Downside)
$685.00 (― Downside)
Blogger Sentiment
Bullish
MX:GNSN Sentiment 100%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth $657.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.88%
12-Months-Change
Fundamentals
Return on Equity
1.60%
Trailing 12-Months
Asset Growth
-6.55%
Trailing 12-Months
Company Description
Genus plc
Genus plc is a global animal genetics company with operations spanning North America, Latin America, the UK, continental Europe, the Middle East, Russia, Africa, and Asia. The business is divided into three key segments: Genus PIC, Genus ABS, and Genus Research and Development. Under its PIC brand, the company provides breeding stock, including sows, boars, and semen, to develop pigs with specific characteristics optimized for pork production. Similarly, for cattle, its ABS, Genus, and Bovec brands offer bull semen and embryos designed to produce calves with advantageous traits for either milk or beef output. Farmers also benefit from a range of specialized technical services, such as semen sexing and reproductive solutions. Genus plc is also strategically collaborating with Beijing Capital Agribusiness Co. Ltd on the research, development, and regulatory approval of porcine reproductive and respiratory syndrome virus (PRRSV)-resistant pigs in China. The company was established in 1994 and is based in Basingstoke, United Kingdom.
GNSN Stock 12 Month Forecast
Average Price Target
$685.00